Literature DB >> 28112443

Decreased expression of VLDLR is inversely correlated with miR-200c in human colorectal cancer.

Bong-Kyu Kim1, Hye-In Yoo1, Ah-Reum Lee1, Keonwoo Choi1, Sungjoo Kim Yoon1.   

Abstract

Colorectal cancer (CRC) is one of the most common cancers and has a high rate of morbidity and mortality worldwide. Very-low-density-lipoprotein receptor (VLDLR), a member of the low-density-lipoprotein receptor (LDLR) superfamily, is a multifunctional receptor that regulates cellular signaling by binding numerous ligands. Several studies reported the altered expression of VLDLR and suggested that VLDLR may play a critical role in tumor development by affecting cell proliferation and metastasis. However, the function of VLDLR and regulation of its expression by miRNAs have not been investigated in CRC. In the present study, we investigated the expression of VLDLR in CRC patients and found it to be significantly decreased in tumors in comparison with paired adjacent non-tumor tissues. Moreover, VLDLR over-expression inhibited the proliferation and migration of CRC cells. We also found that VLDLR expression was negatively regulated by miR-200c in CRC cells and that their expression levels were inversely correlated in CRC patients. These data suggest that VLDLR down-regulation mediated by the increased expression of miR-200c may be involved in the development of CRC.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  VLDLR; colorectal cancer; miR-200c; miRNA

Mesh:

Substances:

Year:  2017        PMID: 28112443     DOI: 10.1002/mc.22618

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  2 in total

1.  Different types of reactions to E7386 among colorectal cancer patient-derived organoids and corresponding CAFs.

Authors:  Toshio Imai; Mie Naruse; Masako Ochiai; Kenji Matsumoto; Satsuki Ikeda; Manami Kani; Yuyu Kato; Akiyoshi Hirayama; Tomoyoshi Soga; Yusaku Hori; Akira Yokoi; Atsushi Ochiai
Journal:  Oncol Lett       Date:  2022-05-23       Impact factor: 3.111

2.  Tanshinol alleviates ulcerative colitis by promoting the expression of VLDLR.

Authors:  Huanhuan Zhu; Shaopeng Tong; Yan Cui; Xiaodong Wang; Minying Wang
Journal:  Drug Dev Res       Date:  2021-06-18       Impact factor: 5.004

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.